| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
|
Lancet
|
2010
|
25.32
|
|
2
|
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
|
Sci Transl Med
|
2011
|
4.51
|
|
3
|
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
|
J Clin Oncol
|
2006
|
2.85
|
|
4
|
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
|
Lancet Oncol
|
2010
|
2.73
|
|
5
|
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.45
|
|
6
|
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
|
Cancer Res
|
2007
|
1.40
|
|
7
|
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
|
J Cancer Res Clin Oncol
|
2013
|
1.18
|
|
8
|
Adipose-derived mesenchymal stem cells and regenerative medicine.
|
Dev Growth Differ
|
2013
|
1.14
|
|
9
|
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
|
Biochem Biophys Res Commun
|
2011
|
1.13
|
|
10
|
Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
|
Int J Oncol
|
2013
|
1.09
|
|
11
|
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
|
Gastric Cancer
|
2011
|
1.08
|
|
12
|
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2012
|
1.00
|
|
13
|
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
|
Int J Cancer
|
2006
|
0.99
|
|
14
|
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
|
Mol Cancer Ther
|
2008
|
0.97
|
|
15
|
Depletion of JARID1B induces cellular senescence in human colorectal cancer.
|
Int J Oncol
|
2013
|
0.96
|
|
16
|
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
|
Int J Cancer
|
2008
|
0.95
|
|
17
|
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
|
Invest New Drugs
|
2009
|
0.93
|
|
18
|
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
|
Gastric Cancer
|
2012
|
0.92
|
|
19
|
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
|
Mol Cancer Ther
|
2010
|
0.91
|
|
20
|
Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.
|
Cancer Lett
|
2006
|
0.88
|
|
21
|
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
|
J Cancer Res Clin Oncol
|
2014
|
0.88
|
|
22
|
Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
|
Jpn J Clin Oncol
|
2008
|
0.88
|
|
23
|
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.87
|
|
24
|
Cancer stem cell theory in gastrointestinal malignancies: recent progress and upcoming challenges.
|
J Gastroenterol
|
2011
|
0.86
|
|
25
|
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
|
Int J Clin Oncol
|
2007
|
0.86
|
|
26
|
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
|
Cancer Sci
|
2012
|
0.84
|
|
27
|
Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
|
J Thorac Oncol
|
2006
|
0.83
|
|
28
|
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
|
Int J Clin Oncol
|
2011
|
0.83
|
|
29
|
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
|
Med Oncol
|
2011
|
0.81
|
|
30
|
Hypoxia and TP53 deficiency for induced pluripotent stem cell-like properties in gastrointestinal cancer.
|
Int J Oncol
|
2012
|
0.81
|
|
31
|
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
|
Cancer Chemother Pharmacol
|
2006
|
0.81
|
|
32
|
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
|
Cancer Sci
|
2012
|
0.80
|
|
33
|
Transcriptomic study of dormant gastrointestinal cancer stem cells.
|
Int J Oncol
|
2012
|
0.80
|
|
34
|
A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).
|
Jpn J Clin Oncol
|
2013
|
0.80
|
|
35
|
Does 1 year adjuvant chemotherapy with oral 5-FUs in colon cancer reduce the peak of recurrence in 1 year and provide long-term OS benefit?
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
36
|
Dicer 1, ribonuclease type III modulates a reprogramming effect in colorectal cancer cells.
|
Int J Mol Med
|
2012
|
0.79
|
|
37
|
Reprogramming of gastrointestinal cancer cells.
|
Cancer Sci
|
2012
|
0.79
|
|
38
|
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.
|
Cancer Sci
|
2012
|
0.79
|
|
39
|
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.78
|
|
40
|
Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors.
|
Jpn J Clin Oncol
|
2009
|
0.78
|
|
41
|
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.
|
Cancer Chemother Pharmacol
|
2012
|
0.77
|
|
42
|
Genotoxic therapy stimulates error-prone DNA repair in dormant hepatocellular cancer stem cells.
|
Exp Ther Med
|
2012
|
0.77
|
|
43
|
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
|
Jpn J Clin Oncol
|
2010
|
0.77
|
|
44
|
microRNA-based cancer cell reprogramming technology.
|
Exp Ther Med
|
2012
|
0.77
|
|
45
|
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
|
J Thorac Oncol
|
2009
|
0.76
|
|
46
|
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.
|
Oncol Lett
|
2011
|
0.75
|
|
47
|
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
|
Anticancer Res
|
2007
|
0.75
|
|
48
|
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
|
Gan To Kagaku Ryoho
|
2016
|
0.75
|
|
49
|
Innovative cell-modifying technology targeting cancer stem cell.
|
Rinsho Ketsueki
|
2013
|
0.75
|
|
50
|
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
|
Future Oncol
|
2015
|
0.75
|
|
51
|
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
52
|
Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
|
J Clin Oncol
|
2011
|
0.75
|
|
53
|
[The concept and significance of cancer stem cells].
|
Nihon Geka Gakkai Zasshi
|
2012
|
0.75
|
|
54
|
[Cancer stem cells depend on their own niche].
|
Gan To Kagaku Ryoho
|
2013
|
0.75
|
|
55
|
Pemetrexed-induced edema of the eyelid.
|
Lung Cancer
|
2006
|
0.75
|
|
56
|
A Phase I/II trial of radiotherapy concurrent with TS-1 plus cisplatin in patients with clinically resectable type 4 or large type 3 gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1205.
|
Jpn J Clin Oncol
|
2013
|
0.75
|
|
57
|
Reversible posterior leukoencephalopathy syndrome and trastuzumab.
|
Invest New Drugs
|
2011
|
0.75
|
|
58
|
Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.
|
Anticancer Res
|
2013
|
0.75
|
|
59
|
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
|
Nihon Rinsho
|
2011
|
0.75
|
|
60
|
Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
|
Dig Surg
|
2017
|
0.75
|